Telisotuzumab vedotin中文名
WebJun 16, 2024 · Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of Teliso-V or Docetax at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 698 adult participants with c-Met … WebSep 2, 2024 · The ADC known as telisotuzumab vedotin is currently undergoing clinical evaluation in MET-expressing NSCLC . This ADC consists of the ABT-700 MET antibody …
Telisotuzumab vedotin中文名
Did you know?
WebApr 16, 2024 · A promising objective response rate (ORR) and a tolerable safety profile were observed with telisotuzumab vedotin (teliso-v; ABBV-399) monotherapy to treat … WebJul 1, 2024 · Abstract. Background: Teliso-V is an anti-c-Met antibody conjugated with a tubulin inhibitor MMAE. The aim of this phase 2 trial (NCT03539536) is to explore safety and efficacy of teliso-V in cohorts (based on histopathology and EGFR mutation) and subgroups (based on c-Met expression) of patients with c-Met+ advanced NSCLC (stage 1), …
WebIntroduction: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive … WebNov 4, 2024 · The use of telisotuzumab vedotin (ABBV-399) plus erlotinib (Tarceva) for patients with c-MET protein expressing non–small cell lung cancer (NSCLC) showed …
WebJan 28, 2024 · Telisotuzumab vedotin. Telisotuzumab vedotin (Teliso-V) is a first-in-class ADC that couples the anti-c-Met humanized mAb with MMAE through a peptide linker. The first-in-human phase I study enrolled 48 patients with pretreated (3 median number of prior lines) advanced solid tumors, ... WebAug 3, 2024 · 这些研究数据初步揭示了 Telisotuzumab Vedotin 对于 c-Met 过表达 NSCLC 患者具有一定的疗效。 c-Met 为一种受体酪氨酸激酶，可通过与其配体肝细胞生长因子结合后，激活多种不同的细胞信号通路，包括有关增殖、运动、迁移及侵袭的细胞信号通路。
WebMay 29, 2024 · Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer. The safety and scientific validity …
WebJan 5, 2024 · Jan 5, 2024. Kristi Rosa. The FDA granted a breakthrough therapy designation to telisotuzumab vedotin for use in patients with advanced or metastatic … fischer hardware havertown paWebJan 4, 2024 · NORTH CHICAGO, Ill., Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the … camping sleeping on sofa cushionsWebtelisotuzumab vedotin（Teliso-V）作用机制（点击图片，查看大图） FDA授予Teliso-V BTD，基于LUMINOSITY研究（Study M14-239）的数据支持。这是一项正在进行的2期研究，旨在确定在二线或三线治疗环境下最适合Teliso-V单药治疗的c-Met过度表达NSCLC目标人群，然后扩大组群以进一步评估Teliso-V在所选人群中的疗效。 fischer hatten poplarville msWebJul 1, 2024 · Background: Teliso-V is an anti-c-Met antibody conjugated with a tubulin inhibitor MMAE. The aim of this phase 2 trial (NCT03539536) is to explore safety and … fischer haus cantinafischer harris \u0026 associatesWebAug 11, 2024 · Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been … fischer harley davidsonWebTelisotuzumab vedotin is an anti-MET ADC targeting MET-overexpressing solid tumors. It has an anti-MET antibody linked to MMAE with a DAR of 3.1. Telisotuzumab vedotin … fischer haus concerts